Head-To-Head Contrast: Assure (OTCMKTS:IONM) versus Interpace Biosciences (OTCMKTS:IDXG)

Valuation and Earnings

This table compares Assure and Interpace Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assure	$250,000.00	0.01	-$26.08 million	($56.12)	0.00
Interpace Biosciences	$38.73 million	0.25	$24.58 million	($0.02)	-110.00

Interpace Biosciences has higher revenue and earnings than Assure. Interpace Biosciences is trading at a lower price-to-earnings ratio than Assure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Assure and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assure	N/A	N/A	N/A
Interpace Biosciences	63.46%	493.02%	137.46%

Insider & Institutional Ownership

3.3% of Assure shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investors. 3.8% of Assure shares are owned by company insiders. Comparatively, 5.5% of Interpace Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Assure has a beta of 219.8, indicating that its stock price is 21,880% more volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Summary

Interpace Biosciences beats Assure on 9 of the 11 factors compared between the two stocks.

About Assure

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.